^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
04/14/2021
Excerpt:
Poorly differentiated neuroendocrine carcinoma/large or small cell: Pembrolizumab can be considered for patients with mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H), or advanced tumor mutational burden-high (TMB-H) tumor(MSI-H). or afvanced tumor mutational burden-high (TMB-H) tumors...
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Small Intestinal Carcinoma)
New
Title:

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

Excerpt:
Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Excerpt:
...- Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is Microsatellite Instability (MSI)-High (MSI-H) OR...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

LITT and Pembrolizumab in Recurrent Brain Metastasis

Excerpt:
...Microsatellite Instability-High Cancer 9....